Significant narrowing of the left main coronary artery is a highrisk condition with significant mortality risk. Bypass surgery is the current gold-standard treatment for unprotected left main (ULM) disease. Stenting utilizing drug-eluting stents (DES) is another therapeutic option for patients with ULM disease considered too high risk for bypass surgery or for patients who simply refuse bypass surgery. We have had great initial success with ULM stenting using DES in 10 selected patients at Baylor University Medical Center. Ongoing multicenter, international randomized studies comparing percutaneous coronary intervention with DES and bypass surgery will shed more light on the best treatment strategy for ULM coronary disease. S ignificant narrowing of the left main (LM) coronary artery is a high-risk condition. Patients with unprotected LM (ULM) disease (unprotected by collateral coronary blood flow or patent bypass grafts) treated medically have an unacceptably high 3-year mortality rate approaching 50% (1, 2) . Trials from the 1970s and 1980s involving patients with LM disease showed a clear survival advantage for bypass surgery over medical therapy (3) , and bypass is the current standard of care for patients with ULM (4) .
ULM coronary artery stenting is another therapeutic option. Initial endeavors using bare-metal stents in the 1980s and 1990s were hampered by high restenosis rates, which commonly manifested as sudden death or the need for a repeat procedure or bypass surgery (5) . The development and release of drug-eluting stents (DES) in 2002, and the dramatic reduction in restenosis associated with DES, have led to a resurgence of interest in ULM stenting. Worldwide experience is accumulating, and initial observational studies have shown short-term outcomes that rival those of bypass surgery. Here we present the Baylor University Medical Center experience with ULM stenting using DES.
Baylor University Medical center experience
Since July 2006, 10 patients have undergone ULM stenting using DES at Baylor University Medical Center. All of the patients except three (patients 8, 9, and 10) were participants of the ongoing SYNTAX trial (6)-a multicenter, multinational, randomized study assessing the safety and efficacy of paclitaxeleluting stents vs bypass surgery for patients with three-vessel coronary disease and/or LM disease. Of the three patients that were not participants of SYNTAX, one patient (patient 9) underwent urgent or bailout ULM stenting secondary to a LM flow-limiting dissection that occurred during left anterior descending coronary artery angioplasty. The other patients (patients 8 and 10) underwent elective ULM stenting after refusing bypass surgery for significant LM and three-vessel coronary disease. All cases have utilized paclitaxel-eluting stents.
Six of the patients were men, and four were women; their mean age was 69 years (Table 1 ). All had typical coronary artery disease risk factors, including hypercholesterolemia (9/10), hypertension (9/10), and tobacco use (2/10 one patient had a formal diagnosis of diabetes mellitus. No patients had prior coronary revascularization procedures. The majority (8/10) had normal left ventricular function with an ejection fraction ≥55%. Most (8/10) presented with an acute coronary syndrome (5/10 with unstable angina, 2/10 with non-ST-elevation myocardial infarction, 1/10 with ST-elevation myocardial infarction), whereas one patient had Canadian Cardiovascular Society class III angina, and one patient was an emergency bailout procedure. The LM lesion location varied (Table 2 ). All patients with distal LM disease had involvement of the LM bifurcation. Of these, 75% also had involvement of the ostial left circumflex coronary artery, 25% had involvement of the ostial left anterior descending coronary artery, and no patient had involvement of both arms of the bifurcation. The six patients with nonbifurcation disease received a single stent in the LM (Figure 1) , and the four patients with involvement of the LM bifurcation required a complex, two-stent technique (Figure 2 ). Coronary segments other than the LM were treated in all patients.
Noninvasive surveillance studies, including computed tomography (CT) coronary angiography and nuclear perfusion imaging studies, were performed 3 to 6 months after ULM stenting. To date, all have been without significant flow-limiting lesions or evidence of ischemia (Table 2 ). Patient 4's surveillance CT coronary angiography was nonconclusive due to dense coronary calcium adjacent to the LM stent, which is a known limitation of CT coronary angiography (7, 8) . The use of CT coronary angiography to assess patency of unprotected left main stents has yet to be validated in clinical trials and is a substudy of SYNTAX. The patient subsequently had a normal nuclear perfusion test and remains asymptomatic. In addition, no adverse clinical events have been reported to date. Patient 7 experienced atypical chest symptoms during supervised exercise, prompting elective coronary angiography at day 38, which revealed patent coronary stents.
discUssion
Significant LM coronary artery disease is a high-risk lesion that compromises blood flow to approximately 75% of the heart. Its prevalence in patients undergoing coronary angiography is 2.5% to 10%, and typically it coexists with other significant narrowings of the coronary tree (9) . Medically treated LM disease has unacceptably high mortality rates (1, 2) . Surgical data from the 1970s and 1980s demonstrated that bypass surgery for LM disease dramatically reduced mortality as compared with medical therapy (68% and 33% relative mortality reduction at 5 and 10 years postbypass) (10) . This clearly established bypass surgery as the gold-standard treatment for LM coronary disease.
Percutaneous treatment of the LM coronary artery was first performed by Andreas Grüntzig in 1977, as reported in his original description of percutaneous transluminal coronary angioplasty (PTCA) (11) . Two of the first five cases of PTCA he reported were in patients with significant LM disease. Procedural complications and the subsequent death of one of these patients led Grüntzig to conclude that LM stenosis was a contraindication to PTCA (12) . With bypass surgery With the advent of bare-metal stents in the 1990s, it became clear that ULM stenting was not only technically feasible but could produce outcomes, depending on the patient cohort, similar to those of bypass surgery (5). However, high restenosis rates with bare-metal stents, often resulting in sudden cardiac death, limited the advancement of ULM stenting during that time period.
With the availability of DES in 2002 and its dramatic reduction in restenosis rates, registry data from multiple centers worldwide showed that using DES for ULM stenting resulted in major adverse cardiovascular event rates similar to those of bypass surgery (13) (14) (15) (16) (17) . In addition, three recent single-center, nonrandomized studies comparing percutaneous coronary intervention (PCI) with DES vs bypass surgery produced outcomes that reflect those of the registry data: PCI showed nonsignificant trends towards lower 6-month (18) and 12-month mortality and myocardial infarction rates (19, 20) . However, they also showed significantly higher 6-month (18) and 12-month target vessel revascularization rates (19, 20) , a reflection of stent restenosis. It's important to point out that restenosis rates of DES used in LM PCI vary dramatically depending on the site of LM stenosis: nondistal LM lesions (i.e., ostial and mid-shaft LM lesions) have extremely low restenosis rates (<5%) (21) , whereas lesions that involve the distal LM bifurcation can have restenosis rates as high as 44% (17, 22) . Stenting of LM bifurcation lesions-where multiple, sometimes overlapping, stents can be required-historically has been challenging for interventionalists. Some observational studies dating back to the bare-metal stent era showed that LM bifurcation lesions can have prohibitively high restenosis rates (23) . Others, however, have not confirmed this finding (24, 25) , and whether this holds true in the DES era remains unanswered. Futhermore, with recent concerns about late stent thrombosis associated with DES, patient compliance with long-term dual antiplatelet therapy is essential.
Baylor University Medical Center is a participating site in SYNTAX (The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) trial (6), which is a multicenter, multinational, randomized study that will assign 1500 consecutive patients with de novo three-vessel coronary disease and/or LM disease to PCI with paclitaxel-eluting stent or bypass surgery. Only patients in whom equivalent revascularization, as determined by both an interventionalist and cardiac surgeon, can be achieved by PCI or bypass will be randomized. All others will be allocated to either a bypass surgery registry (patients who are deemed PCI-ineligible) or a PCI registry (patients who are deemed bypass-ineligible). All patients will be followed out to 5 years. The primary endpoint for randomized comparison is 1-year major adverse cardiovascular and cerebrovascular events, which includes all-cause mortality, myocardial infarction, cerebrovascular events, and repeat revascularizations. Enrollment is now closed, and the early data will be vital in defining the roles of bypass surgery and PCI using DES in the contemporary management of LM disease.
Until randomized trials are completed, ULM stenting using DES can be considered only in select patients: patients who are candidates for revascularization but are not suitable for bypass surgery, either because of confounding comorbidities or patient preference. The ideal patient would have nonbifurcation LM disease (i.e., ostial or mid-shaft) and normal left ventricular function. The use of PCI for these select patients can improve cardiovascular outcomes and is a reasonable revascularization strategy (4). The patient would also have to accept the need for prolonged antiplatelet therapy and likely surveillance follow-up angiography.
